PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33074129-0	2021	Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.	rovalpituzumab tesirine	0-6	programmed cell death 1	Mus musculus	48-51	
33074129-3	2021	Using a pre-clinical murine SCLC tumor model that expresses Dll3 and has an intact murine immune system, we found that sub-efficacious doses of Rova-T with anti-PD1 resulted in enhanced anti-tumor activity, compared to either monotherapy.	rovalpituzumab tesirine	144-150	programmed cell death 1	Mus musculus	161-164	
33074129-7	2021	Whole transcriptome analysis as well as flow cytometry and IHC showed that Rova-T activates dendritic cells and increases Ccl5, Il-12, and Icam more than anti-PD1 alone.	rovalpituzumab tesirine	75-81	programmed cell death 1	Mus musculus	159-162	
33074129-8	2021	Increased tumor expression of PDL1 and MHC1 following Rova-T treatment also supports combination with anti-PD1.	rovalpituzumab tesirine	54-60	programmed cell death 1	Mus musculus	107-110